Study design and rationale for Optimal aNtiplatelet pharmacotherapy guided by bedSIDE genetic or functional TESTing in elective percutaneous coronary intervention patients (ONSIDE TEST): a prospective, open-label, randomised parallel-group multicentre trial (NCT01930773)

• Published in: Kardiologia polska Vol. 74; no. 4; p. 372
• Main Authors: Kołtowski, Łukasz, Aradi, Daniel, Huczek, Zenon, Tomaniak, Mariusz, Sibbing, Dirk, Filipiak, Krzysztof J, Kochman, Janusz, Balsam, Paweł, Opolski, Grzegorz
• Format: Journal Article
• Language: English
• Published: Poland 2016
• Subjects: Adolescent; Adult; Aged; Cytochrome P-450 CYP2C19 - genetics; Humans; Middle Aged; Myocardial Infarction - drug therapy; Myocardial Infarction - etiology; Myocardial Infarction - metabolism; Myocardial Infarction - prevention & control; Percutaneous Coronary Intervention - adverse effects; Pharmacogenomic Testing; Pharmacogenomic Variants; Platelet Aggregation Inhibitors - metabolism; Platelet Aggregation Inhibitors - therapeutic use; Platelet Function Tests; Prasugrel Hydrochloride - metabolism; Prasugrel Hydrochloride - therapeutic use; Prospective Studies; Research Design; Ticlopidine - analogs & derivatives; Ticlopidine - metabolism; Ticlopidine - therapeutic use; Young Adult; clopidogrel; prasugrel; high platelet reactivity; antiplatelet therapy; CYP2C192 allele polymorphism; percutaneous coronary interventions; bedside testing; stable coronary artery disease

High platelet reactivity (HPR) and presence of CYP2C19 loss-of-function alleles are associated with higher risk for periprocedural myocardial infarction in clopidogrel-treated patients undergoing percutaneous coronary intervention (PCI). It is unknown whether personalised treatment based on platelet...